Finanzen von Arcturus Therapeutics Holdings Inc (ARCT)ARCTArcturus Therapeutics Holdings Inc

Evaluating the bottom line, Arcturus Therapeutics Holdings Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -863.30%, while the net margin is -803.82%. These profitability ratios, combined with a Return on Equity (ROE) of -46.31%, provide a clear picture of how effectively ARCT converts its operational activities into shareholder value.

In the context of the broader market, ARCT competes directly with industry leaders such as FULC and TTRX. With a market capitalization of $390.53M, it holds a leading position in the sector. When comparing efficiency, ARCT's gross margin of 100.00% stands against FULC's N/A and TTRX's N/A. Such benchmarking helps identify whether Arcturus Therapeutics Holdings Inc is trading at a premium or discount relative to its financial performance.

The company's gross margin is consistently at 100%, but it has reported significant net losses, with a net income of -$23,785,000 in Q2 2026 and a forward P/E of 2.48, indicating potential undervaluation despite ongoing losses.